Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Adults who have been diagnosed with B-cell non-Hodgkin lymphoma (NHL) that has relapsed or no longer responds to chemotherapy (relapsed or refractory) may be eligible to participate in this study.

graft versus host disease
marginal zone lymphoma
cancer
mantle cell lymphoma
non-hodgkin lymphoma
  • 0 views
  • 19 Feb, 2024
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.

bendamustine
brentuximab vedotin
cutaneous t-cell lymphoma
relapsed t-cell lymphoma
mycosis fungoides and sezary syndrome
  • 0 views
  • 19 Feb, 2024
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

high-grade lymphoma
camrelizumab
neutrophil count
follicular lymphoma grade iiib
b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

recurrent ependymoma
recurrent childhood rhabdomyosarcoma
donor lymphocyte infusion
platelet transfusions
match treatment
  • 0 views
  • 19 Feb, 2024
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

This prospectivemulti-centeropen-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

measurable disease
pet/ct scan
lymphoma
t-cell lymphoma
peripheral t-cell lymphoma
  • 0 views
  • 19 Feb, 2024
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

measurable disease
pet/ct scan
chidamide
azacitidine
lymphoma
  • 0 views
  • 19 Feb, 2024
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

rituximab
malt
cyclophosphamide
marginal zone lymphoma
bortezomib
  • 0 views
  • 19 Feb, 2024
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.

biological therapy
positron emission tomography
measurable disease
electrocardiogram
glucocorticoids
  • 0 views
  • 19 Feb, 2024
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.

chronic lymphocytic leukemia
ejection fraction
cancer
flow cytometry
hematologic malignancy
  • 0 views
  • 19 Feb, 2024
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

chronic lymphocytic leukemia
cell transplantation
lymphoblastic lymphoma
ejection fraction
cancer
  • 0 views
  • 19 Feb, 2024